Clinical Trial

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Study acronym: LOOK-UP
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2024 (before its estimated October 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \& Co. KG.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06498167
Lead Sponsor Universidade do Porto
Collaborators: INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Unidade de Farmacovigilância do Porto, Unidade Local de Saúde São João, Unidade Local de Saúde de Santo António, E.P.E., Unidade Local de Saude de Gaia e Espinho EPE, RISE Health
Conditions Inflammatory Disease, Drug Side Effect, Drug Use, Adverse Drug Event, Adverse Drug Reaction, Safety Issues
Enrollment 150 participants
Start Date 2024-07-01
Primary Completion 2024-10-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-15